Sandbox g12: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 1: | Line 1: | ||
* Risk categories for antimicrobial agents known to have an association with TdP<ref>{{Cite web | title = Arizona Center for Education and Research on Therapeutics | url = http://www.torsades.org }}</ref> | * Risk categories for antimicrobial agents known to have an association with TdP<ref>{{Cite web | title = Arizona Center for Education and Research on Therapeutics | url = http://www.torsades.org }}</ref> | ||
:* '''Drugs with known TdP risk''' | :* '''Drugs with known TdP risk''' | ||
::* [[ | ::* [[Atazanavir|Atazanavir (Reyataz®)]] | ||
::* [[ | ::* [[Bosutinib|Bosutinib (Bosulif®)]] | ||
::* [[ | ::* [[Chlorpromazine|Chlorpromazine (Thorazine®, Largactil®, Megaphen®)]] | ||
::* [[ | ::* [[Cisapride (Removed from US Market)|Cisapride (Removed from US Market) (Propulsid®)]] | ||
::* [[ | ::* [[Epinephrine (Adrenaline)|Epinephrine (Adrenaline) (Primatene®, Bronkaid®)]] | ||
::* [[ | ::* [[Fingolimod|Fingolimod (Gilenya®)]] | ||
::* [[ | ::* [[Gemifloxacin|Gemifloxacin (Factive®)]] | ||
::* [[ | ::* [[Granisetron|Granisetron (Kytril®, Sancuso®, Granisol®)]] | ||
::* [[ | ::* [[Leuprolide (Leuprorelin)|Leuprolide (Leuprorelin) (Lupron®, Eligard®, Viadur®, Carcinil®, Enanton®, Leuplin®, Lucrin®, Procren®, Prostap® and others)]] | ||
::* [[ | ::* [[Mirtazapine|Mirtazapine (Remeron)]] | ||
::* [[Pasireotide|Pasireotide (Signifor®)]] | |||
::* [[Sorafenib|Sorafenib (Nexavar®)]] | |||
:* '''Drugs with possible TdP risk''' | :* '''Drugs with possible TdP risk''' | ||
Revision as of 21:41, 31 May 2015
- Risk categories for antimicrobial agents known to have an association with TdP[1]
- Drugs with known TdP risk
- Atazanavir (Reyataz®)
- Bosutinib (Bosulif®)
- Chlorpromazine (Thorazine®, Largactil®, Megaphen®)
- Cisapride (Removed from US Market) (Propulsid®)
- Epinephrine (Adrenaline) (Primatene®, Bronkaid®)
- Fingolimod (Gilenya®)
- Gemifloxacin (Factive®)
- Granisetron (Kytril®, Sancuso®, Granisol®)
- Leuprolide (Leuprorelin) (Lupron®, Eligard®, Viadur®, Carcinil®, Enanton®, Leuplin®, Lucrin®, Procren®, Prostap® and others)
- Mirtazapine (Remeron)
- Pasireotide (Signifor®)
- Sorafenib (Nexavar®)
- Drugs with possible TdP risk
- Bedaquiline (Sirturo®)
- Dihydroartemisinin-Piperaquine (Eurartesim®)
- Gatifloxacin (Tequin®)
- Gemifloxacin (Factive®)
- Norfloxacin (Noroxin®, Ambigram®)
- Ofloxacin (Floxin®)
- Roxithromycin (Rulide®, Xthrocin®, Roxl-150®, Roxo®, Surlid®, Rulide®, Biaxsig®, Roxar®, Roximycinv®, Roxomycin®, Rulid®, Tirabicin®, Coroxin®)
- Telavancin (Vibativ®)
- Telithromycin (Ketek®)
- Drugs with conditional TdP risk
- Albuterol (salbutamol) (Proventil®, Ventolin®, Ventolin-HFA®, Accuneb®, Combivent®, Vospire-ER®, ProAir HFA®, Duoneb®)
- Haloperidol (Haldol® (US & UK), Aloperidin®, Bioperidolo®, Brotopon®, Dozic®, Duraperidol® (Germany), Einalon S®, Eukystol®, Halosten®, Keselan®, Linton®, Peluces®, Serenace®, Serenase®, Sigaperidol®)
- Isoproterenol (Medihaler-Iso®, Isuprel®)
- Itraconazole (Sporanox®, Onmel®)
- Methylphenidate (Ritalin®, Concerta®, Focalin®, Daytrana®, Methylin®, Metadate CD®)
- Moexipril/HCTZ (Uniretic®, Univasc®)
- Pimozide (Orap®)
- Quetiapine (Seroquel®)
- Risperidone (Risperdal®)
- Tacrolimus (Prograf®, Prograf®, Advagraf®, Protopic®)
- Vemurafenib (Zelboraf®)
- Drugs to be avoided by congenital Long QT
- Torsades de pointes risk stratification schedules for antimicrobial agents[2]
- Schedule I (Highest TdP risk, potent IKr blockers, TdP risk >1%)
- Not available
- Schedule II (Significant risk for TdP, particularly when coadministered with CYP inhibitors, relatively potent IKr blockade)
- Not available
- Schedule III (Risk for TdP is described, IKr blockade, particularly when coadministered with CYP inhibitors)
- Schedule IV (Minimal risk for TdP, case reports of TdP, mild IKr blockade, may have CYP interactions)
- Schedule V (Questionable/minimal risk for QT interval prolongation/TdP)